ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences, Inc. (ASMB: Nasdaq) is a biotechnology company focused on developing innovative therapeutics targeting serious viral diseases. The company's website is www.assemblybio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ASSEMBLY BIOSCIENCES, INC. does
In the company’s own words
Assembly Biosciences, Inc. (ASMB: Nasdaq) is a biotechnology company focused on developing innovative therapeutics targeting serious viral diseases. The company's website is www.assemblybio.com.
Assembly Bio operates a clinical-stage pipeline addressing significant unmet medical needs in virology. The company's primary programs include two long-acting helicase-primase inhibitors for recurrent genital herpes, an orally bioavailable hepatitis delta virus entry inhibitor, a next-generation capsid assembly modulator for hepatitis B virus, and a broad-spectrum non-nucleoside polymerase inhibitor for transplant-associated herpesviruses. In December 2025, the company's lead program for recurrent genital herpes was licensed to Gilead Sciences, Inc., marking a significant validation of Assembly Bio's research and development capabilities.
The company has assembled an accomplished leadership team and research organization with a collective track record of over fifteen approved drugs across multiple viral diseases. Assembly Bio's business model centers on discovering and developing next-generation therapeutics in areas of high unmet medical need with significant market opportunities. The company leverages deep expertise in virology to advance its portfolio toward near-term clinical readouts.
A cornerstone of Assembly Bio's strategy is its collaboration with Gilead Sciences, established in October 2023. Under this arrangement, Gilead made an upfront cash payment of $84.8 million and has committed to extension fees totaling $225 million over the collaboration term. The partnership grants Gilead option rights to Assembly Bio's pipeline programs on a program-by-program basis, with potential option fees ranging from $45 million to $125 million per program. Assembly Bio remains eligible to receive up to $330 million in regulatory and commercial milestones per program, along with tiered royalties on net sales. Additionally, Assembly Bio has the right to opt into a profit-share arrangement covering forty percent of United States research and development costs and profits for optioned programs.
During 2025, Assembly Bio reported positive clinical data across multiple programs, including interim and Phase 1b results for its lead candidates. The company maintains a robust intellectual property portfolio with patent applications covering compositions of matter, methods of use, synthetic processes, and pharmaceutical formulations across its pipeline programs, with expected patent expirations extending through 2045.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1426800
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ASSEMBLY BIOSCIENCES, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ASSEMBLY BIOSCIENCES, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ASSEMBLY BIOSCIENCES, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ASSEMBLY BIOSCIENCES, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ASSEMBLY BIOSCIENCES, INC.'s last four quarterly filings that the numbers alone won't show?”